Benlysta (GlaxoSmithKline) is not only the first drug approved for systemic lupus erythematosus (SLE) in more than 50 years, but also the first biologic approved for the indication. However, uptake…
In 2013, global sales of ethical oncology drugs exceeded $92 million, and sales are expected to exceed $120 million in 2020, far more than the drug revenues of any other therapy area. Thus,…
The TreatmentTrends: Rheumatoid Arthritis 2014 (EU) report explores the treatment dynamics among more than 200 French, German, Italian, Spanish, and UK rheumatologists through comprehensive primary…
In 2013, painful diabetic neuropathy (PDN) affected more than 3.4 million people in the United States. Similar to postherpetic neuralgia, PDN has also served—and continues to serve—as a gateway…
This three-wave LaunchTrends report series will track the post-launch awareness, trial, and usage of Anoro Ellipta among pulmonologists for the treatment of chronic obstructive pulmonary disease (…
This report is a series of four post-launch reports that evaluates the trial and usage of XELJANZ (tofacitinib) among rheumatologists for the treatment of rheumatoid arthritis (RA). LaunchTrends®…
Hepatitis C virus (HCV) chronic infections are a leading cause of advanced liver disease and hepatocellular carcinoma. The first-generation protease inhibitors were a major advancement in the…
Gastrointestinal stromal tumors (GISTs) are rare cancers that belong to a group of cancers known as soft tissue sarcomas, which develop in supporting and connective tissues. GISTs account for…
This LaunchTrends report series will track the post-launch awareness, trial, and usage of Apremilast (Otezla) among rheumatologists for the treatment of Psoriatic Arthritis. Three waves of the…
Do Physicians Have High Hopes for LDL-Lowering Therapies in Cardiovascular Outcomes? As one of the most prevalent diseases in the major pharmaceutical markets, dyslipidemia represents a compelling…
Do Physicians Have High Hopes for LDL-Lowering Therapies in Cardiovascular Outcomes? As one of the most prevalent diseases in the major pharmaceutical markets, dyslipidemia represents a compelling…
Breakthrough therapy designation was introduced by the FDA in 2012 to expedite the drug development process for promising novel therapies for serious or life-threatening conditions. In 2013, of 28…
Major depressive disorder (MDD) continues to be a highly prevalent psychiatric disorder. Over 5 million drug-treated MDD patients in the United States fail to respond adequately to treatment with…
LaunchTrends: Tecfidera (US) is a four-wave syndicated report series that specifically tracks the introduction of Tecfidera, the third-to-market oral disease-modifying therapy (DMT), based on…
Hepatitis C virus (HCV) chronic infections are a leading cause of advanced liver disease and hepatocellular carcinoma. The first-generation protease inhibitors were a major advancement in the…